{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:18:10Z","timestamp":1780377490030,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>With the introduction of novel agents (proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), immuntherapeutics), the outcome of multiple myeloma (MM) patients has improved. The oral PI ixazomib was authorized in the EU in 11\/2016 and is indicated in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed\/refractory MM (RRMM). The study aim was to identify the typical real world (RW) RRMM patient population in Germany treated with IRd and to compare the outcome to prior IRd cohorts. Our retrospective study included consecutive RRMM patients receiving IRd in six large German hospitals between 06\/2017 and 12\/2021. We identified 24 consecutive RRMM patients within these six institutions. Their median age was 68\u00a0years at the start of IRd; 21% carrying high-risk cytogenetics [del17p, t(4;14) and\/or t(14;16)]. Patients had a median of 2 prior treatment lines (range, 1\u20135), prior PI\/IMiD exposure was 100%\/58%, comparable to previous real world evidence (RWE)-studies. With a median follow-up of 37.7\u00a0months, the overall response rate was 70.8%, and median PFS and OS were 22.0 and 62.2\u00a0months, respectively. With these German data, our study is closing an important gap of IRd real world data (RWD) reporting across Europe, providing median PFS\/OS data and comparison to prior IRd studies. IRd is a well-tolerated and effective triplet regimen, often given as 2nd or 3rd-line therapy in RRMM, with results confirming the registration trial and other international RW-analyses.<\/jats:p>","DOI":"10.1007\/s00277-025-06441-8","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:39:18Z","timestamp":1749094758000},"page":"3713-3722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)\u2014multicenter real-world analysis from Germany and comparative review of the literature"],"prefix":"10.1007","volume":"104","author":[{"given":"Hanna","family":"L\u00f6ffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"R\u00e4der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Brioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Klaiber-Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Marie","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Epp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"8","key":"6441_CR1","first-page":"2420","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M (2024) Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica 109(8):2420\u20132435","journal-title":"Haematologica"},{"issue":"5","key":"6441_CR2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","volume":"99","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ramasamy K, Maouche N et al (2020) Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Ann Hematol 99(5):1049\u20131061","journal-title":"Ann Hematol"},{"issue":"9","key":"6441_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","volume":"100","author":"F Davies","year":"2021","unstructured":"Davies F, Rifkin R, Costello C et al (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US. Ann Hematol 100(9):2325\u20132337","journal-title":"Ann Hematol"},{"issue":"19","key":"6441_CR4","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/fon-2020-1225","volume":"17","author":"R H\u00e1jek","year":"2021","unstructured":"H\u00e1jek R, Mina\u0159\u00edk J, Straub J et al (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma. Future Oncol Lond Engl 17(19):2499\u20132512","journal-title":"Future Oncol Lond Engl"},{"issue":"2","key":"6441_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.14214","volume":"113","author":"HC Lee","year":"2024","unstructured":"Lee HC, Ramasamy K, Macro M et al (2024) Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed\/refractory multiple myeloma: A pooled analysis from the INSURE study. Eur J Haematol 113(2):190\u2013200","journal-title":"Eur J Haematol"},{"issue":"9","key":"6441_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt M, Dold SM, Ihorst G et al (2016) Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101(9):1110\u20131119","journal-title":"Haematologica"},{"issue":"5","key":"6441_CR7","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm A-S, Dold SM et al (2017) A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910\u2013921","journal-title":"Haematologica"},{"key":"6441_CR8","doi-asserted-by":"publisher","first-page":"1354760","DOI":"10.3389\/frhs.2024.1354760","volume":"4","author":"JR Hydren","year":"2024","unstructured":"Hydren JR, Lin D, Sweeney NW et al (2024) Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group. Front Health Serv 4:1354760","journal-title":"Front Health Serv"},{"issue":"4","key":"6441_CR9","doi-asserted-by":"publisher","first-page":"151463","DOI":"10.1016\/j.soncn.2023.151463","volume":"39","author":"A Drury","year":"2023","unstructured":"Drury A, O\u2019Brien A, O\u2019Connell L et al (2023) Setting a patient-driven agenda for cancer research priorities in geriatric oncology: A qualitative study. Semin Oncol Nurs 39(4):151463","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"6441_CR10","doi-asserted-by":"publisher","first-page":"e243854","DOI":"10.1001\/jamanetworkopen.2024.3854","volume":"7","author":"JD Peipert","year":"2024","unstructured":"Peipert JD, Zhao F, Lee J-W et al (2024) Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Netw Open 7(3):e243854","journal-title":"JAMA Netw Open"},{"key":"6441_CR11","first-page":"217","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M et al (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217\u2013226","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"6441_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/ejh.13071","volume":"101","author":"K Yong","year":"2018","unstructured":"Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, Hajek R (2018) The start of a new wave: Developments in proteasome inhibition in multiple myeloma. Eur J Haematol 101(2):220\u2013236","journal-title":"Eur J Haematol"},{"issue":"7","key":"6441_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S1470-2045(18)30411-X","volume":"19","author":"HW Auner","year":"2018","unstructured":"Auner HW, Yong KL (2018) More convenient proteasome inhibition for improved outcomes. Lancet Oncol 19(7):856\u2013858","journal-title":"Lancet Oncol"},{"issue":"17","key":"6441_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"22","key":"6441_CR15","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T et al (2021) Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 39(22):2430\u20132442","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"6441_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","volume":"21","author":"J Minarik","year":"2021","unstructured":"Minarik J, Pika T, Radocha J et al (2021) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 21(1):73","journal-title":"BMC Cancer"},{"issue":"8","key":"6441_CR17","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00277-023-05278-3","volume":"102","author":"M Macro","year":"2023","unstructured":"Macro M, Hulin C, Vincent L et al (2023) Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: the REMIX study. Ann Hematol 102(8):2137\u20132151","journal-title":"Ann Hematol"},{"issue":"14","key":"6441_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2217\/fon-2023-0604","volume":"20","author":"X Leleu","year":"2024","unstructured":"Leleu X, Lee HC, Zonder JA et al (2024) INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed\/refractory myeloma in routine practice. Future Oncol Lond Engl 20(14):935\u2013950","journal-title":"Future Oncol Lond Engl"},{"issue":"1","key":"6441_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-021-04663-0","volume":"101","author":"J Sokol","year":"2022","unstructured":"Sokol J, Guman T, Chudej J et al (2022) Ixazomib, lenalidomide, and dexamethasone combination in \u201creal-world\u201d clinical practice in patients with relapsed\/refractory multiple myeloma. Ann Hematol 101(1):81\u201389","journal-title":"Ann Hematol"},{"issue":"4","key":"6441_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s12253-019-00607-2","volume":"25","author":"G Varga","year":"2019","unstructured":"Varga G, Nagy Z, Demeter J et al (2019) Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed\/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program. Pathol Oncol Res POR 25(4):1615\u20131620","journal-title":"Pathol Oncol Res POR"},{"issue":"5","key":"6441_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1080\/10428194.2020.1864356","volume":"62","author":"M Ziff","year":"2021","unstructured":"Ziff M, Lawson G, De-Silva D et al (2021) Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leuk Lymphoma 62(5):1243\u20131246","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"6441_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1080\/10428194.2020.1864355","volume":"62","author":"N Maouche","year":"2021","unstructured":"Maouche N, Kishore B, Jenner MW et al (2021) Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (\u22652nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma 62(6):1396\u20131404","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6441_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12185-022-03479-6","volume":"117","author":"JH Lee","year":"2023","unstructured":"Lee JH, Kim S-H, Kim HR et al (2023) Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and\/or refractory multiple myeloma. Int J Hematol 117(2):225\u2013235","journal-title":"Int J Hematol"},{"key":"6441_CR24","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Mertelsmann R, Duyster J (2023) Das Blaue Buch. Springer","DOI":"10.1007\/978-3-662-67749-0"},{"issue":"20","key":"6441_CR25","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.3390\/cancers14205165","volume":"14","author":"J Minarik","year":"2022","unstructured":"Minarik J, Radocha J, Jungova A et al (2022) Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy. Cancers 14(20):5165","journal-title":"Cancers"},{"issue":"4","key":"6441_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","volume":"13","author":"A Chari","year":"2020","unstructured":"Chari A, Richardson PG, Romanus D et al (2020) Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol 13(4):421\u2013433","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"6441_CR27","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M et al (2021) Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk 21(2):e160\u2013e175","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"6441_CR28","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1002\/cncr.33658","volume":"127","author":"S Scheubeck","year":"2021","unstructured":"Scheubeck S, Ihorst G, Schoeller K et al (2021) Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer 127(18):3422\u20133436","journal-title":"Cancer"},{"issue":"4","key":"6441_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3324\/haematol.2022.281489","volume":"108","author":"M Holler","year":"2023","unstructured":"Holler M, Ihorst G, Reinhardt H et al (2023) An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence. Haematologica 108(4):1115\u20131126","journal-title":"Haematologica"},{"key":"6441_CR30","doi-asserted-by":"crossref","unstructured":"Dreyling E, Ihorst G, Reinhardt H, et al (2024) Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board. Ann Hematol","DOI":"10.1007\/s00277-024-06010-5"},{"issue":"1","key":"6441_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","volume":"286","author":"S Bringhen","year":"2019","unstructured":"Bringhen S, Milan A, D\u2019Agostino M et al (2019) Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the european myeloma network and the italian society of arterial hypertension. J Intern Med 286(1):63\u201374","journal-title":"J Intern Med"},{"issue":"6","key":"6441_CR32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/ejh.14180","volume":"112","author":"R Ayto","year":"2024","unstructured":"Ayto R, Annibali O, Biedermann P et al (2024) The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies. Eur J Haematol 112(6):889\u2013899","journal-title":"Eur J Haematol"},{"issue":"9","key":"6441_CR33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00277-015-2426-8","volume":"94","author":"G Ihorst","year":"2015","unstructured":"Ihorst G, Waldschmidt J, Schumacher M, W\u00e4sch R, Engelhardt M (2015) Analysis of survival by tumor response: have we learnt any better? Ann Hematol 94(9):1615\u20131616","journal-title":"Ann Hematol"},{"issue":"4","key":"6441_CR34","first-page":"1279","volume":"109","author":"K Schoeller","year":"2024","unstructured":"Schoeller K, Ihorst G, Reinhardt H et al (2024) Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications. Haematologica 109(4):1279\u20131284","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06441-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:53:24Z","timestamp":1757181204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6441"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06441-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"25 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institution UKF and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethcial approval"}}]}}